Sun Pharma unit Taro acquires Thallion

20 March 2017

India's biggest drugmaker Sun Pharmaceutical Industries (BSE: 524715) has agreed to acquire Canadian pharmaceuticals firm Thallion Pharmaceuticals from Canada’s Bellus Health.

The cost of the acquisition, which is being effected through Sun’s Taro subsidiary, is C$2.7 million (around $2 million) and includes all the rights to Thallion’s lead drug candidate Shigamab.

Of the total C$2.7 million, C$400,000 is contingent upon the completion of a pre-established milestone event, expected to occur within 24 months of the closing of the transaction. In addition, Bellus Health will receive a portion of certain post-approval revenues related to the Shigamab program.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK